Abstracts

1048 – Alternative Dosing of ABC/3TC Dispersible Tablets to Align With Dolutegravir Dosing in Neonates

Background Rapid maturation of metabolic/elimination pathways during the first month of life complicates using pediatric fixed-dose dispersible formulations in neonates. We previously reported that once daily administration of abacavir/lamivudine dispersible tablets (ABC/3TC-DT) to neonates gave high exposure during the first week of life. Administration of 5 mg dolutegravir (DTG) every 48 hours (q48) for the…

940 – Plasma Biomarkers in Children and Young People With Long COVID

Background Although most patients infected with SARS-CoV-2 recover, 10-20% can develop long-term persistent symptoms after the acute infection, a condition known as long COVID or Post-Acute Sequalae of SARS-CoV-2 (PASC). In this study we aim to compare autoantibodies, cytokines and  neuronal and vascular damage biomarkers in plasma from  children and young people (CYP) with and…

1024 – Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection

Background The global scale-up of prenatal antiretroviral therapy (ART) has reduced the vertical transmission of HIV to <1%. In this context, a growing population of individuals with perinatal HIV exposure without infection (PHEU) has emerged, which now exceeds 20 million people worldwide. While growing evidence indicates that infants and children with PHEU are at increased…

1040 – Germline-Targeting SOSIP Trimer Immunizations Reduced Post-Rebound SHIV Loads in Infant Macaques

Background Globally, >1.4 million children are living with HIV. Life-long ART adherence predisposes children to drug-associated complications, necessitating development of adjunctive therapies that can achieve drug-free viral suppression. Our group recently demonstrated development of VRC01-like broadly neutralizing antibody (bNAb) precursor responses in pediatric rhesus macaques (RMs) upon immunization with a germline-targeting native-like HIV SOSIP trimer.…

1060 – HIV Status Disclosure Among ART-Experienced Adolescents and Young Adults in 4 African Countries

Background Adolescents and young adults living with HIV (ALHIV) face multifaceted challenges to long-term treatment success. We characterized HIV status disclosure among ALHIV and assessed relationships between status disclosure, antiretroviral therapy (ART) adherence and viral suppression. Methods The prospective African Cohort Study enrolls people with and without HIV, ≥15 years, at 12 PEPFAR-supported facilities in Kenya,…

1041 – Immune Correlates of Viral Rebound During Broadly Neutralizing Antibody Treatment in Children

Background Determining immunologic correlates that may be associated with virologic suppression while on alternate or curative HIV therapy is a priority for children. We longitudinally investigated immune responses among participants in the Tatelo Study with and without virologic failure during 6 months of dual bNAb-treatment after ART interruption. Methods Using multiparametric spectral flow cytometry we…

1008 – Impact of Offering PrEP Choice on HIV Incidence in High-Risk Pregnant Women in Kenya

Background HIV incidence remains a significant concern among pregnant and postpartum women. Offering multiple HIV PrEP options can increase coverage and use, yet the impact of HIV infections averted with implementation of various HIV PrEP options for pregnant/postpartum women is unknown. Methods We developed an equation to project HIV incidence through pregnancy and postpartum between…